SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Edvardsen Thor) "

Sökning: WFRF:(Edvardsen Thor)

  • Resultat 1-10 av 41
  • [1]2345Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Almeida, Nuno, et al. (författare)
  • Left atrial volumetric assessment using a novel automated framework for 3D echocardiography: a multi-centre analysis
  • 2017
  • Ingår i: European Heart Journal Cardiovascular Imaging. - : OXFORD UNIV PRESS. - 2047-2404 .- 2047-2412. ; 18:9, s. 1008-1015
  • Tidskriftsartikel (refereegranskat)abstract
    • Aims This study aims at validating a software tool for automated segmentation and quantification of the left atrium (LA) from 3D echocardiography. Methods and results The LA segmentation tool uses a dual-chamber model of the left side of the heart to automatically detect and track the atrio-ventricular plane and the LA endocardium in transthoracic 3D echocardiography. The tool was tested in a dataset of 121 ultrasound images from patients with several cardiovascular pathologies (in a multi-centre setting), and the resulting volumes were compared with those assessed manually by experts in a blinded analysis using conventional contouring. Bland-Altman analysis showed good agreement between the automated method and the manual references, with differences (mean +/- 1.96 SD) of 0.5 +/- 5.7 mL for LA minimum volume and -1.6 +/- 9.7 mL for LA maximum volume (comparable to the inter-observer variability of manual tracings). The automated tool required no user interaction in 93% of the recordings, while 4% required a single click and only 2% required contour adjustments, reducing considerably the amount of time and effort required for LA volumetric analysis. Conclusion The automated tool was validated in a multi-centre setting, providing quantification of the LA volume over the cardiac cycle with minimal user interaction. The results of the automated analysis were in agreement with those estimated manually by experts. This study shows that such approach has clinical utility for the assessment of the LA morphology and function, automating and facilitating the time-consuming task of analysing 3D echocardiographic recordings.
  •  
2.
  • Baturova, Maria A., et al. (författare)
  • Atrial fibrillation as a clinical characteristic of arrhythmogenic right ventricular cardiomyopathy : Experience from the Nordic ARVC Registry
  • 2020
  • Ingår i: International Journal of Cardiology. - : Elsevier. - 0167-5273 .- 1874-1754. ; 298, s. 39-43
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Recent studies in arrhythmogenic right ventricular cardiomyopathy (ARVC) patients have drawn attention to atrial fibrillation (AF) as an arrhythmic manifestation of ARVC and as an indicator of atrial involvement in the disease progression. We aimed to assess the prevalence of AF in the Scandinavian cohort of ARVC patients and to evaluate its association with disease clinical manifestations. Methods: Study sample comprised of 293 definite ARVC patients by 2010 Task Force criteria (TFC2010) and 141 genotype-positive family members (total n = 434, 43% females, median age at ARVC diagnosis 41 years [interquartile range (IQR) 28–52 years]). ARVC diagnostic score was calculated as the sum of major (2 points) and minor (1 point) criteria in all categories of the TFC2010. Results: AF was diagnosed in 42 patients (10%): in 41 patients with definite ARVC diagnosis (14%) vs in one genotype-positive family member (1%), p < 0.001. The median age at AF onset was 51 (IQR 38–58) years. The prevalence of AF was related to the ARVC diagnostic score: it significantly increased starting with the diagnostic score 4 (2% in those with score 3 vs 13% in those with score 4, p = 0.023) and increased further with increased diagnostic score (Somer's d value is 0.074, p < 0.001). Conclusion: AF is seen in 14% of definite ARVC patients and is related to the severity of disease phenotype thus suggesting AF being an arrhythmic manifestation of this cardiomyopathy indicating atrial myocardial involvement in the disease progression.
  •  
3.
  • Borgquist, Rasmus, et al. (författare)
  • The diagnostic performance of imaging methods in ARVC using the 2010 Task Force criteria.
  • 2014
  • Ingår i: European heart journal cardiovascular Imaging. - : Oxford University Press. - 2047-2412. ; 15:11, s. 1219-1225
  • Tidskriftsartikel (refereegranskat)abstract
    • This study evaluates the agreement between echocardiographic and cardiac magnetic resonance (CMR) imaging data, and the impact a discrepancy between the two may have on the clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC).
  •  
4.
  • Brynildsen, Jon, et al. (författare)
  • Circulating secretoneurin concentrations in patients with moderate to severe aortic stenosis
  • 2019
  • Ingår i: Clinical Biochemistry. - : PERGAMON-ELSEVIER SCIENCE LTD. - 0009-9120 .- 1873-2933. ; 71, s. 17-23
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Secretoneurin (SN) concentrations provide important prognostic information in patients with myocardial dysfunction. Whether preoperative SN concentrations improve risk assessment in patients with moderate to severe aortic stenosis (AS) is unknown. Methods: We included 57 patients with moderate to severe AS referred for presurgical evaluation. All patients were examined with comprehensive echocardiography, electrocardiogram (ECG), and biochemical measurements and compared to 10 age- and sex-matched healthy subjects. Results: Median (quartile 1-3) SN concentrations were 141 (121-163) pmol/L in AS patients and 132 (106-148) pmol/L in control subjects (p = .17). Lower estimated creatinine clearance and use of diuretics, but not standard ECG or echocardiographic indices and cardiac biomarkers, were associated with increasing SN concentrations. Fifteen patients (26%) died during 3.5 years median follow-up. SN concentrations were higher in non-survivors than survivors: 156 (133-209) vs. 140 (116-155) pmol/L, p = .007. Higher SN concentrations were associated with increased risk of mortality also after adjustment for established risk indices, biomarkers, and status regarding valvular surgery: hazard ratio per lnSN 15.13 (95% CI 1.05-219.00); p = .046. Receiver operating characteristics area under the curve for SN to predict mortality was 0.74 (95% CI 0.60-0.88) compared to 0.73 (0.59-0.87) for high-sensitivity cardiac troponin T and 0.67 (0.51-0.82) for N-terminal pro-B-type natriuretic peptide. The previously identified cut-off of SN > 204 pmol/L in cardiac surgical patients predicted mortality also in this cohort. Conclusions: SN concentrations improve risk assessment in patients with moderate to severe AS by providing additional prognostic information to established risk indices such as echocardiography, ECG, and established cardiac biomarkers.
  •  
5.
  • Celutkiene, Jelena, et al. (författare)
  • Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies : a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
  • 2020
  • Ingår i: European Journal of Heart Failure. - : WILEY. - 1388-9842 .- 1879-0844. ; 22:9, s. 1504-1524
  • Tidskriftsartikel (refereegranskat)abstract
    • Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.
  •  
6.
  • Christiansen, Morten K, et al. (författare)
  • Incidence, Predictors, and Success of Ventricular Tachycardia Catheter Ablation in Arrhythmogenic Right Ventricular Cardiomyopathy (from the Nordic ARVC Registry).
  • 2020
  • Ingår i: The American journal of cardiology. - : EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC. - 1879-1913 .- 0002-9149. ; 125:5, s. 803-811
  • Tidskriftsartikel (refereegranskat)abstract
    • Catheter ablation may reduce ventricular tachycardia (VT) burden in arrhythmogenic right ventricular cardiomyopathy (ARVC) patients. However, little is known about factors predicting need for ablation. Therefore, we sought to investigate predictors and use of VT ablation and to evaluate the postprocedural outcome in ARVC patients. We studied 435 patients from the Nordic ARVC registry including 220 probands with definite ARVC according to the 2010 task force criteria and 215 mutation-carrying relatives identified through cascade screening. Patients were followed until first-time VT ablation, death, heart transplantation, or January 1st 2018. Additionally, patients undergoing VT ablation were further followed from the time of ablation for recurrent ventricular arrhythmias. The cumulative use of VT ablation was 4% (95% confidence interval [CI] 3% to 6%) and 11% (95% CI 8% to 15%) after 1 and 10 years. All procedures were performed in probands in whom cumulative use was 8% (95% CI 5% to 12%) and 20% (95% CI 15% to 26%). In adjusted analyses among probands, only young age predicted ablation. In patients undergoing ablation, risk of recurrent arrhythmias was 59% (95% CI 44% to 71%) and 74% (95% CI 59% to 84%) 1 and 5 years after the procedure. Despite high recurrence rates, the burden of ventricular arrhythmias was reduced after ablation (p = 0.0042). Young age, use of several antiarrhythmic drugs and inducibility to VT after ablation were associated with an unfavorable outcome. In conclusion, twenty percent of ARVC probands developed a clinical indication for VT ablation within 10 years whereas mutation-carrying relatives were without such need. Although the burden of ventricular arrhythmias decreased after ablation, risk of recurrence was substantial.
  •  
7.
  •  
8.
  •  
9.
  • Flachskampf, Frank A, et al. (författare)
  • Recommendations for transoesophageal echocardiography : EACVI update 2014
  • 2014
  • Ingår i: European Heart Journal Cardiovascular Imaging. - 2047-2404 .- 2047-2412. ; 15:4, s. 353-365
  • Tidskriftsartikel (refereegranskat)abstract
    • With this document, we update the recommendations for transoesophageal echocardiography (TOE) of the European Association of Cardiovascular Imaging. The document focusses on the areas of interventional TOE, in particular transcatheter aortic, mitral, and left atrial appendage interventions, as well as on the role of TOE in infective endocarditis, adult congenital heart disease, and aortic disease.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 41
  • [1]2345Nästa
Typ av publikation
tidskriftsartikel (38)
konferensbidrag (1)
doktorsavhandling (1)
forskningsöversikt (1)
Typ av innehåll
refereegranskat (38)
övrigt vetenskapligt (3)
Författare/redaktör
Edvardsen, Thor (40)
Haugaa, Kristina H. (16)
Lancellotti, Patrizi ... (14)
Gilljam, Thomas (10)
Donal, Erwan (10)
Bundgaard, Henning (10)
visa fler...
Delgado, Victoria (9)
Galderisi, Maurizio (9)
Hansen, Jim (9)
Platonov, Pyotr G (8)
Flachskampf, Frank, ... (8)
Cosyns, Bernard (8)
Engvall, Jan (7)
Habib, Gilbert (7)
Madsen, Trine (7)
Dhooge, Jan (6)
Svendsen, Jesper H. (6)
Cardim, Nuno (6)
Monaghan, Mark (5)
Jensen, Henrik K. (5)
Nagel, Eike (4)
Flachskampf, Frank A ... (4)
Seferovic, Petar (4)
Svensson, Anneli (4)
Jensen, Henrik Kjæru ... (4)
Holst, Anders G (4)
Popescu, Bogdan A (4)
Smiseth, Otto A, (4)
Jaarsma, Tiny (3)
Zamorano, Jose Luis (3)
Ruschitzka, Frank (3)
Mullens, Wilfried (3)
Borgquist, Rasmus (3)
Muraru, Denisa (3)
Platonov, Pyotr (3)
Rosjo, Helge (3)
Svendsen, Jesper Has ... (3)
Carlson, Jonas (3)
Svensson, Anneli, 19 ... (3)
Rademakers, Frank (3)
Omland, Torbjorn (3)
Myhre, Peder L. (3)
Lie, Oyvind H. (3)
Bauersachs, Johann (3)
Gimelli, Alessia (3)
Sicari, Rosa (3)
Stefanidis, Alexandr ... (3)
Sarvari, Sebastian I (3)
Ukkonen, Heikki (3)
Nagueh, Sherif F. (3)
visa färre...
Lärosäte
Linköpings universitet (18)
Uppsala universitet (15)
Göteborgs universitet (9)
Lunds universitet (9)
Karolinska Institutet (3)
Kungliga Tekniska Högskolan (1)
Språk
Engelska (41)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (34)
Teknik (3)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy